دورية أكاديمية

LBA3 Compartmental radioimmunotherapy (cRIT) 131I-OMBURTAMAB in patients with neuroblastoma (NB) central nervous system (CNS) and/or leptomeningeal (LM) metastases: Updated results from pivotal Trial 101

التفاصيل البيبلوغرافية
العنوان: LBA3 Compartmental radioimmunotherapy (cRIT) 131I-OMBURTAMAB in patients with neuroblastoma (NB) central nervous system (CNS) and/or leptomeningeal (LM) metastases: Updated results from pivotal Trial 101
المؤلفون: Basu, E., Mora, J., Streby, K., Bear, M., Sano, H., Marachelian, A., Harrison, D., Nysom, K., Pandit-Taskar, N., Zanzonico, P., Fabricius, S., During, M., Nielsen, J.R., Kramer, K.
المصدر: In Immuno-Oncology and Technology December 2022 16 Supplement 1
قاعدة البيانات: ScienceDirect
الوصف
تدمد:25900188
DOI:10.1016/j.iotech.2022.100364